The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study

GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10–20%. GCSF has been suggested as a possible adjunct to immunotherapy due to increased peripheral neutrophil recruitment and PD-L1 expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Anpalakhan, Shobana, Huddar, Prerana, Behrouzi, Roya, Signori, Alessio, Cave, Judith, Comins, Charles, Cortellini, Alessio, Addeo, Alfredo, Escriu, Carles, McKenzie, Hayley, Barone, Gloria, Murray, Lisa, Bhatnagar, Gagan, Pinato, David J., Ottensmeier, Christian, Gomes, Fabio, Banna, Giuseppe Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867035/
https://www.ncbi.nlm.nih.gov/pubmed/36675262
http://dx.doi.org/10.3390/ijms24021746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867035/
https://www.ncbi.nlm.nih.gov/pubmed/36675262
http://dx.doi.org/10.3390/ijms24021746

Ejemplares similares